|
| 36670111 | Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. | NPJ Genom Med | 2023 |
| 34426440 | Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response. | Clin Cancer Res | 2022 |
| 35130500 | Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 35238467 | Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience. | Mol Oncol | 2022 |
| 32700810 | Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. | Int J Cancer | 2021 |
| 33571625 | Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer. | Int J Radiat Oncol Biol Phys | 2021 |
| 33735448 | Predictors and significance of histologic response to neoadjuvant therapy for gastric cancer. | J Surg Oncol | 2021 |
| 34607609 | Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. | Genome Med | 2021 |
| 34375311 | SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. | JCI Insight | 2021 |
| 34326133 | Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity. | Clin Cancer Res | 2021 |
| 34340212 | Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2021 |
| 33009371 | Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. | Nat Commun | 2020 |
| 31782524 | Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. | Int J Cancer | 2020 |
| 31058253 | Revisiting Epidermal Growth Factor Receptor (<i>EGFR</i>) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. | JCO Precis Oncol | 2019 |
| 31773431 | Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors. | Cancer Metastasis Rev | 2019 |
| 31801585 | Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. | J Hematol Oncol | 2019 |
| 33015522 | Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. | JCO Precis Oncol | 2019 |
| 31297829 | Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: Retrospective analysis of an International Patient Registry. | J Surg Oncol | 2019 |
| 31320401 | Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. | Mol Cancer Ther | 2019 |
| 31032472 | Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. | JCO Precis Oncol | 2019 |
| 29133621 | The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA. | Mol Cancer Ther | 2018 |
| 32913983 | Genomic Landscape of Appendiceal Neoplasms. | JCO Precis Oncol | 2018 |
| 29891520 | NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. | J Natl Compr Canc Netw | 2018 |
| 30348637 | Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. | Clin Cancer Res | 2018 |
| 29523662 | A Novel <i>PRKAR1B-BRAF</i> Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy. | J Natl Compr Canc Netw | 2018 |
| 29211306 | Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients. | Cancer | 2018 |
| 28807936 | Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. | Cancer Res | 2017 |
| 29938249 | Duodenal-Jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic <i>NF1</i> and Notch Pathway Mutations. | JCO Precis Oncol | 2017 |
| 28114506 | Surgical Management of Adolescents and Young Adults With Gastrointestinal Stromal Tumors: A US Population-Based Analysis. | JAMA Surg | 2017 |
| 28476734 | The Call of "The Wild"-Type GIST: It's Time for Domestication. | J Natl Compr Canc Netw | 2017 |
| 28939679 | Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. | Cancer Res | 2017 |
| 26945010 | A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. | Ann Oncol | 2016 |
| 27697982 | Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2016 |
| 27637150 | A systematic review of clinically available gene expression profiling assays for stage II colorectal cancer: initial steps toward genetic staging. | Am J Surg | 2016 |
| 27974047 | FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. | J Transl Med | 2016 |
| 27185373 | Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. | Clin Cancer Res | 2016 |
| 26857926 | Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. | Cancer Metastasis Rev | 2016 |
| 26873727 | Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. | Mol Cancer Ther | 2016 |
| 26848768 | Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. | Oncotarget | 2016 |
| 27025710 | Population-Based Epidemiology and Mortality of Small Malignant Gastrointestinal Stromal Tumors in the USA. | J Gastrointest Surg | 2016 |
| 24638008 | In vivo imatinib sensitivity in a patient with GI stromal tumor bearing a PDGFRA deletion DIM842-844. | J Clin Oncol | 2015 |
| 26489442 | A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. | Ann Oncol | 2015 |
| 26418953 | Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. | Oncotarget | 2015 |
| 26083491 | ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer. | PLoS One | 2015 |
| 25852059 | On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. | Mol Cancer Ther | 2015 |
| 25928476 | Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. | Cell Cycle | 2015 |
| 25950492 | Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. | Cell Cycle | 2015 |
| 25695927 | Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. | Cell Cycle | 2015 |
| 25691612 | Esophageal and esophagogastric junction cancers, version 1.2015. | J Natl Compr Canc Netw | 2015 |
| 25596748 | Cyclin alterations in diverse cancers: Outcome and co-amplification network. | Oncotarget | 2015 |